# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

The assigned 510(k) number is: K100263

# Submitter Address Phone number Fax number

SEPPIM S.A.S.   
Zone Industrielle, 61500 SEES, FRANCE $^ +$ 33 (0)2 33 81 21 00   
$^ +$ 33 (0)2 33 28 77 51

# Contact

Valérie GOURDON (Email: v.gourdon@elitechgroup.com)

Date of Preparation Friday, January $2 2 ^ { n d }$ 2010

# Device names

# REAGENT :

Trade/proprietary Name: ELITech Clinical Systems ELICAL 2 Common or Usual Name: Calibrator, multi-analyte mixture, "ELICAL 2" Device Class Class II Classification name Calibrator (21 CFR 862.1150) Product code JIX- Calibrator, multi-analyte mixture

# Predicate device

# Roche Diagnostics Calibrator for Automated Systems (C.f.a.s) (K033501)

# Device description

ELITech Clinical Systems ELICAL 2 is a lyophilized calibrator based on human serum containing constituents to ensure optimal calibration.

ELICAL 2 is prepared exclusively from the blood of donors tested individually and found to be negative for HbsAg and to antibodies to HCV and HIV according to FDA-approved methods or methods in compliance with the European Directive 98/79/EC, Annex II, List A.

# Intended Use

ELTech Clinical Systems LICAL s a multi-parametric calibrator or n v diagnostic use in the calibration of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

# Comparison to Predicate device

<table><tr><td rowspan=1 colspan=1>-t                a s ti</td><td rowspan=1 colspan=1>ELITech Clinical Systems Device    (ELICAL 2)</td><td rowspan=1 colspan=1>Predicate device(Roche Calibrator f.a.s.)</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>ELITech Clinical Systems ELICAL2 is a multi-parametric calibratorfor in vitro diagnostic use in thecalibration of quantitative ELITechClinical Systems methods on theVital Scientific Selectra JuniorAnalyzer and the Vital ScientificFlexor Junior Analyzer.</td><td rowspan=1 colspan=1>For in vitro diagnostic use in thecalibration of quantitative Rochemethods on Roche clinicalchemistry analysers as specified inthe value sheets.</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized calibrator based onhuman serum with constituentsadded as required to obtain desiredcomponents levels</td><td rowspan=1 colspan=1>Lyophilized calibrator based onhuman serum with constituentsadded as required to obtain desiredcomponents levels</td></tr><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>Single level</td><td rowspan=1 colspan=1>Single level</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Carefully open the vial, avoiding theloss of lyophilate, and pipette inexactly 3 mL of distilled/deionizedwater. Carefully close the vial anddissolve the contents completely byoccasional gentle swirling within 30minutes avoiding the formation offoam.</td><td rowspan=1 colspan=1>Carefully open one bottle, avoidingthe loss of lyophilate, and pipette inexactly 3 mL of distilled/deionizedwater. Carefully close the bottle anddissolve the contents completely byoccasional gentle swirling within 30minutes. Avoid the formation offoam.</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Traceability information is given inthe value sheet included in the box.</td><td rowspan=1 colspan=1>Traceability of the target value isgiven in the respective instructionfor use of the system reagents.</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Lyophilized:To store at 2-8°C and protectedfrom light until the expiry dateAfter reconstitution, the stabilitiesare :- 8 hours between 15-25 °C.- 2 days between 2-8 °C.- 4 weeks between -25 and -15 °C(when frozen once)</td><td rowspan=1 colspan=1>Lyophilized:Stable at 2-8°C up to expirationdate.After reconstitution, the stabilities*are :- 8 hours at 15-25 °C.- 2 days at 2-8 °C.- 4 weeks at (-25)-(-15) °C (whenfrozen once)*Exception for bilirubin total &amp; directas noted in package insert</td></tr></table>

# Conclusion

The performance data and other information demonstrate that the safety and effectiveness of this device versus the predicate device is not compromised, and that it met all acceptance criteria, demonstrating that the device is substantially equivalent to its respective predicate device.

# SECTION 5 - 510(k) Summary ELITech Clinical Systems UREA UV SL reagent

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

The assigned 510(k) number is: K100263

# Submitter Address Phone number Fax number

SEPPIM S.A.S.   
Zone Industrielle, 61500 SEES, FRANCE + 33 (0)2 33 81 21 00   
+ 33 (0)2 33 28 77 51

# Contact

Valérie GOURDON (Email: v.gourdon@elitechgroup.com)

Date of Preparation

Friday, January 22d 2010

# Device names

# REAGENT :

Trade/proprietary Name: ELITech Clinical Systems UREA UV SL

Common or Usual Name:   
Device Class   
Classification name   
Product code   
Urea nitrogen, ukEA uv SL"   
Class II   
Urea nitrogen test system (Sec.862.1770)   
CDQ - Urease And Glutamic Dehydrogenase, Urea Nitrogen

# Predicate device

ABX PENTRA UREA CP (K060205, K070146)

# Device description

The device for this submission is available as kit only. It consists of 2 reagents: Reagent 1 contains Tris buffer (pH 7.60), Adenosine diphosphate potassium salt (ADP), a-Ketoglutarate, Urease (jack bean), Glutamate dehydrogenase (GIDH) (bovine liver) and sodium azide.   
Reagent 2 contains NADH and sodium azide

# Intended Use

ELITech Clinical Systems UREA UV SL is intended for use with ELITech Clinical Systems ELICAL 2 and ELITech Clinical Systems ELITROL I and ELITROL II on Vital Scientific Selectra/Flexor analyzers for the quantitative in vitro diagnostic determination of urea nitrogen in human serum and plasma. It is not intended for use in Point of Care settings.

# Indication(s) for Use

ELITech Clinical Systems UREA UV SL is intended to measure urea nitrogen in human serum and plasma. Urea nitrogen measurements are used in the diagnosis and treatment of certain renal and metabolic diseases.

# Comparison to Predicate device

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ELITech&#x27;Clinical Systems DeviceUREA UV SL</td><td rowspan=1 colspan=1>Predicate device    &quot;, t,(ABX PENTRA UREA CP)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Intended for use withELITechClinical Systems ELICAL 2 andELITech Clinical Systems ELITROL Iand ELITROL II on Vital ScientificSelectra/Flexor analyzers for thequantitative in vitro diagnosticdetermination of urea nitrogen inhuman serum and plasma.It is not intended for use in Point ofCare settings.</td><td rowspan=1 colspan=1>For in vitro diagnostic use in thequantitative determination ofurea/urea nitrogen in serum, plasmaand urine.</td></tr><tr><td rowspan=1 colspan=1>Indication(s) for Use</td><td rowspan=1 colspan=1>Intended to measure urea nitrogenin human serum and plasma. Ureanitrogen measurements are used inthe diagnosis and treatment ofcertain   renal   and   metabolicdiseases.</td><td rowspan=1 colspan=1>Urea nitrogen measurements areused in the diagnosis and treatmentof certain renal and metabolicdiseases.</td></tr><tr><td rowspan=1 colspan=1>Assay protocol</td><td rowspan=1 colspan=1>Enzymatic UV method using Ureaseand Glutamate dehydrogenase</td><td rowspan=1 colspan=1>Enzymatic UV method using Ureaseand Glutamate dehydrogenase</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>Reagent R1:Tris buffer, pH 7.60    125 mmol/L ;ADP                       1 mmol/L;α-Ketoglutarate           9 mmol/L ;Urease                  ≥ 8 100 U/L;GIDH                   ≥ 1 350 U/L ;Sodium azide                &lt; 0.1%;Reagent R2:NADH                    1.5 mmol/L;Sodium azide                &lt; 0.1%;</td><td rowspan=1 colspan=1>Reagent 1:Tris buffer, pH 7.8     150 mmol/L;2-Oxoglutarate        8.75 mmol/L ;ADP                    0.75 mmol/L;Urease                 ≥ 7 500 U/L;GIDH                   2 1 250 U/L ;Sodium azide                &lt; 1 g/L;Reagent 2:NADH                  1.32 mmol/L ;Sodium azide                &lt; 1 g/L;</td></tr><tr><td rowspan=1 colspan=1>Appearance of reagent</td><td rowspan=1 colspan=1>Liquid form, ready to use</td><td rowspan=1 colspan=1>Liquid form, ready to use</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>SerumPlasma in lithium heparin</td><td rowspan=1 colspan=1>SerumPlasma in lithium heparinUrine</td></tr><tr><td rowspan=1 colspan=1>Reagent storage</td><td rowspan=1 colspan=1>Store at 2-8 C and protected fromlight. The reagents are stable untilthe expiry date stated on the label.</td><td rowspan=1 colspan=1>Reagents, in unopened cassette, arestable up to expiry date on the labelif stored at 2-8 °C and contaminationavoided.</td></tr><tr><td rowspan=1 colspan=1>Expected values</td><td rowspan=1 colspan=1>Serum, plasma:Urea nitrogen (BUN)Adults (21-60 years6-20 mg/dLAdults (60-90 years)8-23 mg/dLAdults (&gt; 90 years) 10-31 mg/dL</td><td rowspan=1 colspan=1>Serum, plasma:Urea nitrogen (BUN)Adults:Global :             7.9-20.2 mg/dLWomen &lt; 50 years 7.3-18.8 mg/dLWomen &gt; 50 years 9.8-20.2 mg/dLMen &lt; 50 years    9.0-20.5 mg/dLMen &gt; 50 years    8.4-25.8 mg/dLChildren:1-3 years           5.1-16.8 mg/dL4-13 years          7.0-16.8 mg/dL</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ELlTech Clinical Systems DeviceUREA UV SL</td><td rowspan=1 colspan=1>Predicate device(ABX PENTRA UREA CP)</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>14-19 years        8.1-21.1 mg/dL</td><td></td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>SELECTRA JUNIOR</td><td rowspan=1 colspan=1>ABX PENTRA 400</td><td></td></tr><tr><td rowspan=1 colspan=1>Measuring range*</td><td rowspan=1 colspan=1>4.7 to 140.0 mg/dLExtended measuring range : 140.0to 670.0 mg/dL</td><td rowspan=1 colspan=1>1.03 to 140.3 mg/dLAutomatic post-dilution: 701.5 mg/dL</td><td></td></tr><tr><td rowspan=1 colspan=1>Limit of detection (LoD)*</td><td rowspan=1 colspan=1>0.3 mg/dL</td><td rowspan=2 colspan=1>0.9 mg/dL</td><td></td></tr><tr><td rowspan=1 colspan=1>Limit of quantification(LoQ)*</td><td rowspan=1 colspan=1>2.3 mg/dL</td><td></td></tr><tr><td rowspan=1 colspan=1>Precision*</td><td rowspan=1 colspan=1>Within runLevel 7.3 mg/dLCV=2.1%Level 29.2 mg/dL CV=0.8%Level 72.4 mg/dL CV=0.7%TotalLevel 7.3 mg/dLCV=2.8%Leve! 29.2 mg/dL CV=1.3%Level 72.4 mg/dL CV=1.6%</td><td rowspan=1 colspan=1>Within runLevel 18.7 mg/dL CV=2.27%Level772.8 mg/dLCV=1.66%Level 6.0 mg/dL CV=2.76%Levei 20.9 mg/dLCV=1.58%Level 85.5 mg/dL CV=1.80%TotalLevel18.5 mg/dL CV=2.14%Level71.7 mg/dL CV=1.93%Level19.2 mg/dL CV=2.14%Level 70.1 mg/dL CV=1.97%</td><td></td></tr><tr><td rowspan=1 colspan=1>Method comparison*</td><td rowspan=1 colspan=1>y=0.991 x + 0.6 mg/dLr= 0.999range: 4.4 to 139.8 mg/dL</td><td rowspan=1 colspan=1>y=0.99 x - 0.06 mg/dL$^{2}=096range: 1.03 to 138.89 mg/dL</td><td></td></tr><tr><td rowspan=1 colspan=1>Limitations</td><td rowspan=1 colspan=1>Hemoglobin:    No    significantinterference up to 500 mg/dL.Turbidity:      No      significantinterference upto 614mg/dLtriglyceride equivalent.Unconjugated    bilirubin:    Nosignificant interference upto 30mg/dL.Conjugated bilirubin: No significantinterference up to 29.5 mg/dL.Ascorbic acid: No significantinterference up to 20 mg/dL.Methyldopa: No significantinterference up to 1· mg/dL.</td><td rowspan=1 colspan=1>Hemoglobin: No significantinfluence is observed up to 460mg/dL.Triglycerides: No significantinfluence is observed up to 612.5mg/dL.Total bilirubin: No significantinfluence is observed up to 22.23mg/dL.Direct bilirubin: No significantinfluence is observed up to 23.40mg/dL.</td><td></td></tr><tr><td rowspan=1 colspan=1>Calibration Frequency</td><td rowspan=1 colspan=1>7 days</td><td rowspan=1 colspan=1>8 days</td><td></td></tr><tr><td rowspan=1 colspan=1>On board stability</td><td rowspan=1 colspan=1>refrigerated area : 14 days</td><td rowspan=1 colspan=1>refrigerated area: 70 days</td><td></td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Recommended calibration material(not included):ELITech Clinical Systems Elical 2</td><td rowspan=1 colspan=1>Recommended calibration material(not included):ABX Pentra Multical</td><td></td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Recommended quality controlmaterial (not included):ELITech Clinical Systems Elitrol I</td><td rowspan=1 colspan=1>Recommended quality controlmaterial (not included):ABX Pentra N Control</td><td></td></tr></table>

<table><tr><td></td><td>ELITech Clinical Systems Device UREA UV SL</td><td>Predicate device (ABX PENTRA UREA CP)</td></tr><tr><td rowspan="3"></td><td>(Normal control)</td><td>(Normal control)</td></tr><tr><td>ELITech Clinical Systems Elitrol II</td><td>ABX Pentra P Control (Pathologic</td></tr><tr><td>(Pathologic control)</td><td>control)</td></tr></table>

\* : values expressed in BUN

# Conclusion

The performance data and other information demonstrate that the safety and effectiveness of this device versus the predicate device is not compromised, and that it met all acceptance criteria, demonstrating that the device is substantially equivalent to its respective predicate device.

# SECTION 5 - 510(k) Summary ELITech Clinical Systems PHOSPHORUS reagent

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

The assigned $5 1 0 ( 1 \kappa )$ number is: K100263

Submitter Address Phone number Fax number

SEPPIM S.A.S.   
Zone Industrielle, 61500 SEES, FRANCE + 33 (0)2 33 81 21 00   
+ 33 (0)2 33 28 77 51

# Contact

Valérie GOURDON (Email: v.gourdon@elitechgroup.com)

Date of Preparation

Friday, January $2 2 ^ { \pi ^ { d } }$ 2010

# Device names

# REAGENT :

Trade/proprietary Name:   
Common or Usual Name:   
Device Class   
Classification name   
Product code

ELITech Clinical Systems PHOSPHORUS Inorganic phosphorus, "PHOSPHORUS" Class I Phosphorus (inorganic) test system (Sec.862.1580) CEO - Phosphomolybdate (colorimetric), inorganic phosphorus

# Predicate device

ABX PENTRA PHOSPHORUS CP (K060205, K070249)

# Device description

The device for this submission is available as kit only. It consists of 1 reagent R.   
Reagent R consists of sulfuric acid and ammonium molybdate.

# Intended Use

ELITech Clinical Systems PHOSPHORUS is intended for use with ELITech Clinical Systems ELICAL 2 and ELITech Clinical Systems ELITROL I and ELTROL I on Vital Scientic Selectra/Flexor analyzers or the quantitative vitro diagnostic determination of inorganic phosphorus in human serum and plasma. It is not intended for use in Point of Care settings.

Indication(s) for Use

ELITech Clinical Systems PHOSPHORUS is intended to measure inorganic phosphorus in human serum and plasma. (Inorganic) phosphorus measurements are used in the diagnosis and treatment of various disorders, including parathyroid gland and kidney diseases, and vitamin D imbalance.

# Comparison to Predicate device

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">ELITech Clinical Systems DevicePHOSPHORUS</td><td colspan="1" rowspan="1">      Predicate device(ABX PENTRA PHOSPHORUS CP)</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">Intended for use withELITechClinical Systems ELICAL 2 andELITech Clinical Systems ELITROL Iand ELITROL i on Vital ScientificSelectra/Flexor analyzers for thequantitative  in vitro diagnosticdetermination     of     inorganicphosphorus in human serum andplasma. It is not intended for use inPoint of Care settings.</td><td colspan="1" rowspan="1">For in vitro diagnostic use in thequantitative determination ofphosphorus in serum, plasma andurine.</td></tr><tr><td colspan="1" rowspan="1">Indication for Use</td><td colspan="1" rowspan="1">Intendedtomeasure  inorganicphosphorus in human serum andplasma.(Inorganic) phosphorusmeasurements are used in thediagnosis and treatment of variousdisorders,  including parathyroidgland and kidney diseases, andvitamin D imbalance.</td><td colspan="1" rowspan="1">Measurements of phosphorus(inorganic) are used in the diagnosisand treatment of various disorders,including parathyroid gland andkidney diseases, and vitamin Dimbalance.</td></tr><tr><td colspan="1" rowspan="1">Assay protocol</td><td colspan="1" rowspan="1">UV method usingphosphomolybdate</td><td colspan="1" rowspan="1">UV method usingphosphomolybdate</td></tr><tr><td colspan="1" rowspan="1">Composition</td><td colspan="1" rowspan="1">Reagent R:Sulfuric acid             210 mmol/L;Ammonium molybdate 650 μmol/L :</td><td colspan="1" rowspan="1">Reagent:Sulfuric acid            210 mmol/L;Ammonium molybdate650 μmol/L;</td></tr><tr><td colspan="1" rowspan="1">Appearance of reagent</td><td colspan="1" rowspan="1">Liquid form, ready to use</td><td colspan="1" rowspan="1">Liquid form, ready to use</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">SerumPlasma in lithium heparin</td><td colspan="1" rowspan="1">SerumPlasma in lithium heparinUrine</td></tr><tr><td colspan="1" rowspan="1">Reagent storage</td><td colspan="1" rowspan="1">Store at 2-25 C and protected fromlight. The reagent is stable until theexpiry date stated on the label.</td><td colspan="1" rowspan="1">Reagents, in unopened cassette, arestable up to expiry date on the labelif stored at 2-8 C.</td></tr><tr><td colspan="1" rowspan="1">Expected values</td><td colspan="1" rowspan="1">Serum, plasma : 2.7 - 4.5 mg/dL</td><td colspan="1" rowspan="1">Serum, plasma : 2.7 - 4.5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">SELECTRA JUNIOR</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">Measuring range</td><td colspan="1" rowspan="1">2.0 to 20.0 mg/dL</td><td colspan="1" rowspan="1">0.30 to 24.18 mg/dLAutomatic post-dilution: 96.72 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limit of detection (LoD)</td><td colspan="1" rowspan="1">0.02 mg/dL</td><td colspan="1" rowspan="2">0.28 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limit of quantification (LoQ)</td><td colspan="1" rowspan="1">1.00 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Precision</td><td colspan="1" rowspan="1">Within runLevel 2.37 mg/dL CV=1.1%Level 4.80 mg/dL CV=1.5%Level 9.55 mg/dL CV=1.7%</td><td colspan="1" rowspan="1">Within runLevel 4.08 mg/dL CV=1.25%Level6.34 mg/dl. CV=0.77%Level2.39 mg/dL CV=2.48%Level3.48 mg/dLCV=1.61%Level9.19 mg/dLCV=1.38%</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">ELITech Clinical Systems DevicePHOSPHORUS     $</td><td colspan="1" rowspan="1">Predicate device(ABX PENTRA PHOSPHORUS CP)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">TotalLevel 2.37 mg/dL CV=1.9%Level 4.80 mg/dL CV=1.7%Level9.55 mg/dL CV=2.2%</td><td colspan="1" rowspan="1">TotalLevel4.01 mg/dL CV=2.50%Level6.35 mg/dL CV=1.82%Level2.50 mg/dL CV=3.56%Level11.44 mg/dL CV=1.38%</td></tr><tr><td colspan="1" rowspan="1">Method comparison</td><td colspan="1" rowspan="1">y=0.999 - 0.09 mg/dLr= 0.999range: 2.02 to 20.08 mg/dL</td><td colspan="1" rowspan="1">y=1.04x + 0.15 mg/dL$^{2}=0.998range: 0.30 to 24.08 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limitations</td><td colspan="1" rowspan="1">Hemoglobin: No significantinterference is observed up to 50mg/dL Unconjugated bilirubin: Nosignificant interference is observedup to 15 mg/dLConjugated bilirubin: No significantinterference is observed up to 1.5mg/dL.Glucose: No significant interferenceis observed up to 500 mg/dL.Triglycerides:    No   significantinterference is observed up to 732mg/dL.</td><td colspan="1" rowspan="1">Hemoglobin: No significantinfluence is observed up to 125.mg/dL.Triglycerides: No significantinfluence is observed up to 262.5mg/dL.Total bilirubin: No significantinfluence is observed up to 6 mg/dL.Direct bilirubin: No significantinfluence is observed up to 25mg/dL.</td></tr><tr><td colspan="1" rowspan="1">Calibration Frequency</td><td colspan="1" rowspan="1">28 days</td><td colspan="1" rowspan="1">34 days</td></tr><tr><td colspan="1" rowspan="1">On board stability</td><td colspan="1" rowspan="1">refrigerated area : 28 days</td><td colspan="1" rowspan="1">refrigerated area: 70 days</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Recommended calibration material(not included):ELITech Clinical Systems Elical 2</td><td colspan="1" rowspan="1">Recommended calibration material(not included):ABX Pentra Multical</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Recommended quality controlmaterial (not included):ELITech Clinical Systems Elitrol I(Normal control)ELITech Clinical Systems Elitrol II(Pathologic control)</td><td colspan="1" rowspan="1">Recommended quality controlmaterial (not included):ABX Pentra N Control(Normal control)ABX Pentra P Control (Pathologiccontrol</td></tr></table>

# Conclusion

The performance data and other information demonstrate that the safety and effectiveness of this device versus the predicate device is not compromised, and tha it me all acceptance riteridemonstratinghat the device  substantially equivalent to its respective predicate device.

# SECTION 5 - 510(k) Summary ELITech Clinical Systems URIC ACID MONO SL reagent

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

The assigned 510(k) number is: K100263

Submitter Address Phone number Fax number

SEPPIM S.A.S.   
Zone Industrielle, 61500 SEES, FRANCE + 33 (0)2 33 81 21 00   
+ 33 (0)2 33 28 77 51

# Contact

Valérie GOURDON (Email: v.gourdon@elitechgroup.com)

Date of Preparation

Friday, January 22d 2010

# Device names

# REAGENT :

Trade/proprietary Name: ELITech Clinical Systems URIC ACID MONO SL Common or Usual Name: Uric acid, "URIC ACID MONO SL" Device Class Class I Classification name Uric acid test system (Sec.862.1775) Product code KNK - Acid; Uric, Uricase (colorimetric)

# Predicate device

ABX PENTRA Uric acid CP (K060205, K081276)

# Device description

The device for this submission is available as kit only. It consists of 1 reagent R. Reagent R consists of Phosphate buffer (pH 7.0), N-Ethyl-N-(2-Hydroxy-3- Sulfopropyl $m$ Toluidine (EHSPT). Ferrocyanide, Amino-4-antipyrine (4-AAP), Uricase (microorganisms), Peroxidase (horseradich) and sodium azide.

# Intended Use

ELITech Clinical Systems URIC ACID MONO SL is intended for use with ELITech Clinical Systems ELICAL 2 and ELITech Clinical Systems ELITROL 1 and ELITROL II on Vital Scientific Selectra/Flexor analyzers for the quantitative in vitro diagnostic determination of uric acid in human serum and plasma. It is not intended for use in Point of Care settings.

# Indication(s) for Use

ELITech Clinical Systems URIC ACID MONO SL is intended to measure uric acid in human serum and plasma. Uric acid measurements are used in the diagnosis and treatment of numerous renal and metabolic disorders, including renal failure, gout, leukemia, psoriasis, starvation or other wasting conditions, and of patients receiving cytotoxic drugs.

# Comparison to Predicate device

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">ELITech Clinical Systems DeviceURIC ACID MONO SL</td><td colspan="1" rowspan="1">Predicate device(ABX PENTRA URIC ACID CP)</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">Intended for use with ELITechClinical Systems ELICAL 2 andELITech Clinical Systems ELITROL Iand ELITROL II1 on Vital ScientificSelectra/Flexor analyzers for thequantitative in vitro diagnosticdetermination of uric acid in humanserum and plasma.It is not intended for use in Point ofCare settings.</td><td colspan="1" rowspan="1">For in vitro diagnostic use in thequantitative determination of uricacid in serum, plasma and urine.</td></tr><tr><td colspan="1" rowspan="1">Indication(s) for Use</td><td colspan="1" rowspan="1">Intended to measure uric acid inhuman serum and plasma. Uric acidmeasurements are used in thediagnosis   and  treatmentnumerous;renal and metabolicdisorders, including renal failure,gout, leukemia, psoriasis, starvationor other wasting conditions, and ofpatients receiving cytotoxic drugs.</td><td colspan="1" rowspan="1">Uric acid measurements are used inthe diagnosis and treatment ofnumerous renal and metabolicdisorders, including renal failure,gout, leukemia, psoriasis, starvationor other wasting conditions, and ofpatients receiving cytotoxic drugs.</td></tr><tr><td colspan="1" rowspan="1">Assay protocol</td><td colspan="1" rowspan="1">Enzymatic determination using achromgenic system in the presenceof peroxidase and uricase (Trindermethod).</td><td colspan="1" rowspan="1">Enzymatic determination using achromgenic system in the presenceof peroxidase and uricase (Trindermethod).</td></tr><tr><td colspan="1" rowspan="1">Composition</td><td colspan="1" rowspan="1">Reagent R:Phosphate buffer; pH 7.0 100 mmol/L;EHSPT                   0.72 mmol/L;Ferrocyanide            0.03 mmol/L ;Amino-4-antipyrine      0.37 mmol/L ;Uricase                     ≥ 150 U/L;Peroxidase              ≥ 12 000 U/L :Sodium azide                  &lt; 0.1%;</td><td colspan="1" rowspan="1">Reagent 1:Phosphate buffer, pH 7.0 125 mmol/L ;EHSPT                   1.38 mmol/L;Ascorbate oxidase       ≥ 1 100 U/L;Bovine albumin                  0.2 %;Sodium azide                  &lt;0.1%Reagent 2:4-Aminoantipyrine        1.8 mmol/L ;Uricase                     ≥ 700 U/L;Peroxidase                ≥ 7 500 U/LFerrocyanide              250 μmol/L ;Bovine albumin                  0.2 %;Sodium azide                  &lt;0.1%;</td></tr><tr><td colspan="1" rowspan="1">Appearance of reagent</td><td colspan="1" rowspan="1">Liquid form, ready to use</td><td colspan="1" rowspan="1">Liquid form, ready to use</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">SerumPlasma in lithium heparin</td><td colspan="1" rowspan="1">SerumPlasma in lithium heparinUrine</td></tr><tr><td colspan="1" rowspan="1">Reagent storage</td><td colspan="1" rowspan="1">Store at 2-8 °C and protected fromlight. The reagent is stable until theexpiry date stated on the label.</td><td colspan="1" rowspan="1">Reagents, in unopened cassette, arestable up to expiry date on the labelif stored at 2-8 °C.</td></tr><tr><td colspan="1" rowspan="1">Expected values</td><td colspan="1" rowspan="1">Serum, plasmaWomen:    2.6 - 6.0 mg/dLMen:        3.5 - 7.2 mg/dL</td><td colspan="1" rowspan="1">Serum, plasmaWomen:   2.6 - 6.0 mg/dLMen:        3.5 - 7.2 mg/dL</td></tr><tr><td colspan="3">ELITech Clinical Systems Device. URIC ACID MONO SL</td></tr><tr><td>Instrument</td><td>SELECTRA JUNIOR</td><td>(ABX PENTRA URIC.ACID CP) ABX PENTRA 400</td></tr><tr><td>Measuring range</td><td>1.5 to 25.0 mg/dL Extended measuring range : 25 to 78 mg/dL</td><td>0.18 to 25.00 mg/dl. Automatic post-dilution: 75.00 mg/dL</td></tr><tr><td>Limit of detection (LoD)</td><td>0.02 mg/dL</td><td>0.19 mg/dL</td></tr><tr><td>Limit of quantification (LoQ) Precision</td><td>0.50 mg/dL Within run Level 2.49 mg/dL CV=0.8%</td><td>Within run Level 4.62 mg/dL CV=0.45%</td></tr><tr><td></td><td>Level 5.19 mg/dL CV=1.3% Level 7.63 mg/dL CV=1.1% Total Level 2.49 mg/dL CV=2.6% Level 5.19 mg/dL CV=2.0% Level 7.63 mg/dL CV=2.1%</td><td>Level 11.63 mg/dL CV=0.34% Level 2.53 mg/dL CV=1.24% Level 4.58 mg/dL CV=0.91% Level 7.19 mg/dL CV=1.02% Total Level 4.64 mg/dL CV=2.81% Level 11.73 mg/dL CV=1.39% Level 4.67 mg/dL CV=2.64% Level 6.74 mg/dL CV=2.51%</td></tr><tr><td>Method comparison Limitations</td><td>y=1.015 x + 0.03 mg/dL r= 0.999 range: 1.49 to 24.40 mg/dL Hemoglobin: No significant interference up to 50 mg/dL.</td><td>y=0.95 x + 0.09 mg/dL $^{2096 range: 0.18 to 23.59 mg/dL Hemoglobin: No significant</td></tr><tr><td></td><td>Unconjugated bilirubin: No significant interference up to 30 mg/dL Conjugated bilirubin: No significant interference up to 14.8 mg/dL. Glucose: No significant interference up to 500 mg/dL. Ascorbic acid: Significant interference on samples containing ascorbic acid. Triglycerides:. No significant interference up to 1070 mg/dL. Methyldopa: No significant interference up to 1 mg/dL. Calcium dobesilate: Induces falsely low results on individuals taking</td><td>influence is observed up to 500 mg/dL. Triglycerides: No significant influence is observed up to 612.5 mg/dL. Total bilirubin: No significant influence is observed up to 36 mg/dL. Direct bilirubin: No significant influence is observed up to 30 mg/dL. 15 days</td></tr><tr><td>Calibration Frequency</td><td>calcium dobesilate. 28 days</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">ELITech Clinical Systems DevicemURIC ACID MONO SL</td><td colspan="1" rowspan="1">Predicate device(ABX PENTRA URIC ACID CP)</td></tr><tr><td colspan="1" rowspan="1">On board stability</td><td colspan="1" rowspan="1">refrigerated area : 28 days</td><td colspan="1" rowspan="1">refrigerated area: 41 days</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Recommended calibration material(not included):ELITech Clinical Systems Elical 2</td><td colspan="1" rowspan="1">Recommended calibration material(not included):ABX Pentra Multical</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Recommended quality controlmaterial (not included):ELITech Clinical Systems Elitrol I(Normal control)ELITech Clinical Systems Elitrol II(Pathologic control)</td><td colspan="1" rowspan="1">Recommended quality controlmaterial (not included):ABX Pentra N Control(Normal control)ABX Pentra P Control (Pathologiccontrol)</td></tr></table>

# Conclusion

The performance data and other information demonstrate that the safety and effectiveness of this device versus the predicate device is not compromised, and that it met all acceptance criteria, demonstrating that the device is substantially equivalent to its respective predicate device.

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

The assigned 510(k) number is: K100263

# Submitter Address Phone number Fax number

SEPPIM S.A.S.   
Zone Industrielle, 61500 SEES, FRANCE $^ +$ 33 (0)2 33 81 2100   
+ 33 (0)2 33 28 77 51

# Contact

Valérie GOURDON (Email: v.gourdon@elitechgroup.com)

Date of Preparation Friday, January $2 2 ^ { n d }$ 2010

# Device names

# CONTROLS:

# ELITech Clinical Systems ELITROL I and ELITROL II

Trade/proprietary Name:   
Common or Usual Name:   
Device Class   
Classification name   
Product code   
Multi-analyte controls - all kinds, "ELITROL I". "ELITROL II   
Class I   
Quality control material (assayed and unassayed). (21 CFR 862.1660)   
JJX- Multi-analyte controls - all kinds

# Predicate device

Roche Diagnostics Precinorm U (K041227) Roche Diagnostics Precipath U (K041227)

# Device description

ELITech Clinical Systems ELITROL I and ELITROL II are two level quality contro! products consisting of lyophilized human serum containing constituents at desired levels.

Elitrol I and Elitrol II are prepared exclusively from the blood of donors tested individually and found to be negative for HbsAg and to antibodies to HCV and HIV according to FDA-approved methods or methods in compliance with the European Directive 98/79/EC, Annex II, List A.

# Intended Use

ELITech Clinical Systems ELITROL I is a multi-parametric control serum for in vitro diagnostic use in accuracy control of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

ELITech Clinical Systems ELITROL II is a multi-parametric control serum for in vitro diagnostic use in accuracy control of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

# Comparison to Predicate device

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ELITech Clinical Systems DeviceELITROLT/ELITROLII</td><td rowspan=1 colspan=1>Predicate DeviceRoche Precinorm U / Precipath U</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>ELITech Clinical Systems ELITROL I is amulti-parametric control serum for in vitrodiagnostic use in accuracy control ofquantitative ELITech Clinical Systemsmethods on the Vital Scientific SelectraJunior Analyzer and the Vital ScientificFlexor Junior Analyzer.ELITech Clinical Systems ELITROL II isa multi-parametric control serum for invitro diagnostic use in accuracy controlof quantitative ELITech Clinical Systemsmethods on the Vital Scientific SelectraJunior Analyzer and the Vital ScientificFlexor Junior Analyzer.</td><td rowspan=1 colspan=1>For in vitro diagnostic use in qualitycontrol by monitoring accuracy andprecision for the quantitative methodsas specified in the value sheet.</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized human sera with constituentsadded as required to obtain desiredcomponents levels</td><td rowspan=1 colspan=1>Lyophilized human sera withconstituents added as required toobtain desired components levels</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Two levels</td><td rowspan=1 colspan=1>Two levels</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Carefully open the vial, avoiding the lossof lyophilate, and pipette in exactly 5 mLof distilled/deionized water. Carefullyclose the vial and dissolve the contentscompletely by occasional gentle swirlingwithin 30 minutes avoiding the formationof foam.</td><td rowspan=1 colspan=1>Carefully open the bottle, avoiding theloss of lyophilate, and pipette in exactly5 mL of distilled/deionized water.Carefully close the bottle and dissolvethe contents completely by occasionalgentle swirling within 30 minutes.Avoid the formation of foam.</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Lyophilized:To store at 2-8°C and protected fromlight until the expiry dateAfter reconstitution, the stabilities are :- 12 hours between 15-25 °C.- 5 days between 2-8 °C.- 4 weeks between -25 and -15 °C (whenfrozen once)</td><td rowspan=1 colspan=1>Lyophilized:Stable at 2-8°C up to expiration date.After reconstitution, the stabilities* are :- 12 hours at 15-25 °C.- 5 days at 2-8 °C.- 4 weeks at (-25)-(-15) °C (whenfrozen once)*Exception for bilirubin total &amp; direct asnoted in package insert</td></tr><tr><td rowspan=1 colspan=3>Conclusion            The performapce data and other infer:</td></tr></table>

The performance data and other information demonstrate that the safety and effectiveness of these devices versus the predicate devices are not compromised, and that it met all acceptance criteria, demonstrating that the device is substantially equivalent to its respective predicate device.

ELITech Group Epoch Biosciences   
c/o Debra Hutson   
$2 1 7 2 0 2 3 ^ { \mathrm { r d } }$ Dr., SE, Suite 150   
Bothell, WA 98021

Re: k100263 Trade/Device Name: ELITech Clinical Systems Urea UV SL Regulation Number: 21 CFR 862.1770 Regulation Name: Urea nitrogen test system Regulatory Class: Class II Product Code: CDQ, KNK, CEO, JIX, JJY Dated: 30 March 2011 Received: 04 April 2011 MAY - 6 2011

Dear: Ms. Hutson,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls.Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Ac or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division  Posarket Survellance t (3017-70For questions regardi the reporting of adverse events under the MDR regulation (21 CFR Part 803), please g to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/dab4c121c001f528974974bdcfec295f7165aa385d2d7e4cbfe41f3e4b327c1f.jpg)

Courtny C. Harper, Ph.D.   
Directr   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use Form

510(k) Number (if known): _K100263

Device Name: ELITech Clinical Systems PHOSPHORUS

Indications for Use:

ELITech Clinical Systems PHOSPHORUS reagent is for the quantitative in vitro diagnostic determination of inorganic phosphorus in human serum and plasma on the Vital Scientific Seléctra/Flexor analyzers.

It is not intended for use in Point of Care settings.

Measurements of phosphorus (inorganic) are used in the diagnosis and treatment of various disorders, including parathyroid gland and kidney diseases, and vitamin D imbalance.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/f42cf4006241e098064030c975f65e1f11721542c55dbb663442f2ef5685e348.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K100263

# Indications for Use Form

510(k) Number (if known): _K100263

Device Name: ELITech Clinical Systems URIC ACID MONO SL

Indications for Use:

ELITech Clinical Systems URIC ACID MONO SL reagent is for the quantitative in vitro diagnostic determination of uric acid in human serum and plasma on the Vital Scientific Selectra/Flexor analyzers.

It is not intended for use in Point of Care settings.

Measurements obtained by this device are used in the diagnosis and treatment of numerous renal and metabolic disorders, including renal failure, gout, leukemia, psoriasis, starvation or other wasting conditions, and of patients receiving cytotoxic drugs.

Prescription Use _X_ Over-The-Counter Use AND/OR (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/f13a76f4e7b71dc74559d3d35f73b9153361100c6625031a7083a25931cf57e4.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k)K100263

# Indications for Use Form

510(k) Number (if known): __K100263_

Device Name: ELITech Clinical Systems UREA UV SL.

Indications for Use:

ELITech Clinical Systems UREA UV SL reagent is for the quantitative in vitro diagnostic determination of urea nitrogen in human serum and plasma on the Vital Scientific Selectra/Flexor analyzers.

It is not intended for use in Point of Care settings.

Measurements obtained by this device are used in the diagnosis and treatment of certain renal and metabolic diseases.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/8a6a41dfd3cb27812fdc97acdf3ba68d46c8dec78917544370b06f0882b642e2.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K100263

# Indications for Use Form

510(k) Number (if known): _K100263

Device Name: ELITech Clinical Systems ELICAL 2_

Indications for Use:

ELITech Clinical Systems ELICAL 2 is a multi-parametric calibrator for in vitro diagnostic use in the calibration of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

Prescription Use __X Over-The-Counter Use AND/OR (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/3ebed50d9f418f8a8b71e5a612fa10b6ce2af1cdb828e0152901bcde61001b05.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K100 263

# Indications for Use Form

510(k) Number (if known): _K100263

Device Name: ELITech Clinical Systems ELITROL 1 and ELITROL 2_

Indications for Use:

ELITech Clinical Systems ELITROL I is a multi-parametric control serum for in vitro diagnostic use in accuracy control of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

ELITech Clinical Systems ELITROL Il is a multi-parametric control serum for in vitro diagnostic use in accuracy control of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior analyzer and the Vital Scientific Flexor Junior analyzers.

Prescription Use __X_ Over-The-Counter Use AND/OR (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/a57d4d551c7119c98ee5faeadc5464881d42b1b3665e6559dd41c79975fd23b2.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) k/00263